Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
Open Access
- 4 August 2010
- Vol. 116 (16), 3830-3834
- https://doi.org/10.1002/cncr.25247
Abstract
BACKGROUND: The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. METHODS: Data from 87 patients with MDS (n = 67) and chronic myelomonocytic leukemia (n = .20) after failure of decitabine regimens were reviewed. RESULTS: After a median follow‐up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12‐month survival rate was 28%. The estimated 12‐month survival rates were 27%, 33%, and 33%, respectively, for patients with high‐risk, intermediate‐2‐risk, and intermediate‐1‐risk disease (P = .99) by the International Prognostic Scoring System. The estimated 12‐month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low‐risk, intermediate‐1‐risk, intermediate‐2‐risk, and high‐risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P = .01). CONCLUSIONS: The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 10 references indexed in Scilit:
- Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemCancer, 2008
- Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.Blood, 2007
- Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndromeCancer, 2007
- Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaBlood, 2006
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002
- International Scoring System for Evaluating Prognosis in Myelodysplastic SyndromesBlood, 1997
- Evaluation of survival data and two new rank order statistics arising in its consideration.1966